Windlas Biotech Limited (WINDLAS) - Total Liabilities

Latest as of September 2025: Rs2.80 Billion INR ≈ $30.29 Million USD

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has total liabilities worth Rs2.80 Billion INR (≈ $30.29 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Windlas Biotech Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Windlas Biotech Limited - Total Liabilities Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see WINDLAS total asset value.

Windlas Biotech Limited Competitors by Total Liabilities

The table below lists competitors of Windlas Biotech Limited ranked by their total liabilities.

Company Country Total Liabilities
H+H International A/S
CO:HH
Denmark Dkr1.65 Billion
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
India Rs-8.52 Billion
QST International
TWO:8349
Taiwan NT$14.47 Billion
Rithm Acquisition Corp.
NYSE:RAC
USA $8.12 Million
Brompton Split Banc Corp
TO:SBC
Canada CA$237.75 Million
Armada Acquisition Corp. II
NASDAQ:XRPN
USA $255.87 Million
Meeka Metals Ltd
AU:MEK
Australia AU$43.12 Million
Leenos Corp
KQ:039980
Korea ₩11.99 Billion

Liability Composition Analysis (2018–2025)

This chart breaks down Windlas Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Windlas Biotech Limited (WINDLAS) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.52 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Windlas Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Windlas Biotech Limited (2018–2025)

The table below shows the annual total liabilities of Windlas Biotech Limited from 2018 to 2025.

Year Total Liabilities Change
2025-03-31 Rs2.55 Billion
≈ $27.54 Million
+44.48%
2024-03-31 Rs1.76 Billion
≈ $19.06 Million
+39.12%
2023-03-31 Rs1.27 Billion
≈ $13.70 Million
+31.66%
2022-03-31 Rs962.33 Million
≈ $10.41 Million
-0.79%
2021-03-31 Rs970.04 Million
≈ $10.49 Million
-24.70%
2020-03-31 Rs1.29 Billion
≈ $13.93 Million
+23.17%
2019-03-31 Rs1.05 Billion
≈ $11.31 Million
-36.55%
2018-03-31 Rs1.65 Billion
≈ $17.83 Million
--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic
Market Cap
$250.31 Million
Rs23.15 Billion INR
Market Cap Rank
#15731 Global
#794 in India
Share Price
Rs1098.15
Change (1 day)
-2.75%
52-Week Range
Rs718.35 - Rs1154.75
All Time High
Rs1154.75
About

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more